Ablative radiation appears to be an effective monotherapy for oligometastatic renal cell carcinoma (RCC), so might it maximize disease control when added to immunotherapy? This NCDB analysis compares outcomes for the minority of patients receiving immunotherapy for RCC (n=644) also receiving ablative radiation (10%) to those who didn’t (90%). Importantly, 71% of radiation-treated sites were brain mets. Overall survival at 2 years for those who did versus didn’t receive radiation was 71% versus 59%, respectively. This difference was most pronounced across the 110 patients with brain mets who did (n=45) versus didn’t (n=65) receive radiation for whom survival at 2 years was 71% versus 51%. | Piening, Adv Radiat Oncol 2023
